A specialty pharmaceutical company with offices in China and the US focuses on product development and sales and marketing in four therapeutic areas: clinical nutrition, oncology, antibiotics and respiratory. The company is interested in forming partnerships with biopharmaceutical companies that are interested in entering the Chinese market. The company is flexible in terms of partnering models, which includes in-licensing, co-development, exclusive distribution, joint venture, and product acquisition. The company is actively seeking products from the US and Europe.

The firm has a primary focus in seeking products in Phase II/III or already been approved or launched in US or EU and in Surgery, Pediatric, Respiratory, ICU, Oncology and Nephrology areas. However, the company will also look into the products in Cardiovascular, Clinical nutrition and Pain management, but these are not our priority for now. Eddingpharm is equally interested in other areas with unmet medical needs in China (such as CNS, GI, Nephrology, etc). The company will consider both small molecules and biologics. The firm is most interested in NCE or NCE-like molecules. The firm will only consider biosimilar or generics if there are no similar products or very few players with identical chemical/biological structure in China. In terms of phase of development, the firm will consider marketed and early-late clinical stage products for the five listed areas above. For other therapeutic areas, the company is looking for assets that have obtained regulatory approval in the US or Europe markets.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in New Jersey makes initial investments from $5-$10M with $25M over the lifetime of the company. The firm invests globally, and has particular experience with partners in US, Israel, and England.

The firm seeks early-stage nanotechnology and stem cell research, particularly in cancer, rehabilitation, and regenerative medicine. The firm is only interested in clinical stage Ph I/II technology. The firm focuses their expertise in regenerative medicine, stem cell biology, immunology, oncology, and nanotechnology to identify opportunities in the treatment of a broad range of diseases. Specific to oncology, the firm is interested in novel cancer therapies, immunotherapy, new chemotherapies, targeted therapy, management of adverse consequences, and quality of life improvement.

The firm requires management teams with experience in the field. The firm seeks board representation post-investment, and remains actively supportive with portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A cross-border venture capital firm with offices in the USA and Asia is currently investing from its new $80 million fund closed in 2017. The firm’s LPs include pharmaceutical companies. Typically the firm makes an initial investment ranging from under $1 million to $3-6 million dependent on the company’s stage of development. The firm can allocate up to $16 million over the lifetime of a company. The firm invests in early-stage therapeutic companies worldwide, with a focus on opportunities in North America.

The firm only invests in therapeutics, and is primarily focused on companies with preclinical or clinical assets. Within therapeutics, all modalities are of interest. The firm may invest up to 18 months prior to IND, however require that a company has a lead asset that has been characterized. The firm will consider opportunities in any indication area.

The firm invests in teams with experienced, highly motivated teams with a strong background in either life science research or industry. The firm only invests in companies with technology that has the potential to be first in class.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A global pharmaceutical company with offices in Japan and the USA focuses on developing and marketing products in the pharmaceutical and nutraceutical businesses. Currently, the firm is actively seeking in-licensing opportunities to strengthen their product portfolio, and will consider all global opportunities.

The firm is interested in innovative therapeutics that address areas of significant unmet need in the following indications: CNS, nephrology, and oncology, in descending order. CNS is the area in which the firm has the strongest interest and expertise, and the firm is opportunistic to all types of sub-indications that fall under CNS, including Alzheimer’s disease, schizophrenia, etc. In nephrology, the firm is particularly interested in therapeutics in chronic kidney disease (CKD) and complications that are linked to CKD (i.e. hyponatremia), as well as IgA nephropathy and acute kidney injury. In oncology, the firm is primarily interested in therapeutics being developed for hematological cancers. The firm will consider assets as early as pre-clinical, but such assets will ideally be IND-ready with a valid proof-of-concept.

The firm has no specific management team requirements and will work with all types of companies with an innovative product or pipeline. The firm does not always seek distribution rights.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A private equity firm based in New York previously invested in real estate, retail, and consumer products and has recently focused on life science investment opportunities. The firm is investing from their current $300M fund and also plans to raise a $200M fund focused on life sciences and consumer products. The firm’s minimum investment begins at $5M, and the investment size depends on the stage of the targeted company. The firm primarily invests in later stage life science companies. The firm is looking for companies in North America, and would seek distribution rights in China. The firm is actively looking for investment opportunities and plans to make 4-5 new investments as soon as possible. The firm would only seek to be the lead investor and will request a board seat.

The firm is a flexible and opportunistic investor that is currently considering Therapeutics, Medical Devices, Diagnostics, and Healthcare IT companies. The firm is open to all kinds of sectors but prefers companies that are into phase I of clinical trials or later. The firm is especially interested in vaccines including flu vaccines, Hepatitis A vaccine, Hepatitis B vaccine, and any other drugs for common diseases in China. The firm has a strong preference for later stage companies with products and pipelines that can directly produce and sell in China. The firm is open to medical devices with all FDA regulatory pathways, including 510k, PMA, and software-enabled devices. The firm is open to any phases in medical devices and therapeutics with a preference for those within human data. The most important consideration is the potential market in China.

The firm considers the management team’s character and entrepreneurial spirit. Team members who speak Mandarin may be a plus.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An investment group based in New York City is currently investing in early stage biotechnology companies and company creation from dedicated capital. These investments are typically standalone and/or syndicated with a network of investors that have invested with the firm in the past. The firm founds 1-2 companies per year by creating a company around an asset that they acquired or in-licensed. The firm also considers investments in 0-3 existing companies per year, which are typically early in the company’s development and/or follow-on investments. The firm invests globally but requires the company or development programs have a North America component.

The firm is a flexible and opportunistic investor and will consider any therapeutics area. The firm focuses on drug development and makes occasional investments in therapeutic devices. The firm focuses on clinical stage drug development opportunities, but may consider earlier stage products if the drug is a repositioning/reformulation opportunity or has some human safety data in another indication and/or territory. The firm will generally focus on single therapeutic assets and avoids diagnostics, platforms, and computational biology companies that lack any drug assets. The firm looks at any area of medicine and focuses on niche areas of medicine and smaller indications.

The firm is open to both lead and co-investing depending on the opportunity. However, typically the firm will not be a lead on a large raise. If the firm creates the company they will be a very active, hands-on investor. The firm is open to investing in very young companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A global pharmaceutical company based in Europe forms in-licensing and partnering relationships with early stage therapeutic companies worldwide. The firm also has a corporate venture group which makes equity investments in early stage companies.

The firm’s focus areas are Cardiometabolic disease, CNS, Immunology, Oncology, and Respiratory diseases. Therapeutic opportunities beyond these focus areas may be considered by the corporate venture fund or by an internal research group, which assesses very early-stage emerging areas of science. The firm considers both small molecule and biologic assets but is generally not interested in cell therapy technologies. The firm prefers to consider assets that have attained proof of concept data (in vitro or in vivo) linking the treatment’s mechanism of action to the disease process.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com